Armata Pharmaceuticals (ARMP) EBIT Margin (2013 - 2020)

Armata Pharmaceuticals has disclosed EBIT Margin across 6 years of filings, most recently posting 14806.45% for Q2 2020.

• EBIT Margin for Q2 2020 came in at 14806.45%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2020 was 17661.54% (changed N/A YoY), and the FY2017 annual result was 14048.7%, down 505716.0% from the prior year.
• EBIT Margin came in at 14806.45% for Q2 2020 at Armata Pharmaceuticals, down from 11825.0% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 1963.16% in Q3 2017 to a low of 53927.27% in Q4 2016.
• The 3-year median for EBIT Margin is 11748.28% (2016), against an average of 16465.83%.
• Across the five-year window, EBIT Margin plunged 5163040 bps in 2016 and surged 4210227 bps in 2017, its largest moves.
• Armata Pharmaceuticals' EBIT Margin stood at 53927.27% in 2016, then jumped by 78 bps to 11825.0% in 2017, then slipped by 25 bps to 14806.45% in 2020.
• The last three EBIT Margin figures came in at 14806.45% (Q2 2020), 11825.0% (Q4 2017), and 1963.16% (Q3 2017), per Business Quant data.